These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 27054485)

  • 41. 3-Substituted 3-(4-aryloxyaryl)-propanoic acids as GPR40 agonists.
    Walsh SP; Severino A; Zhou C; He J; Liang GB; Tan CP; Cao J; Eiermann GJ; Xu L; Salituro G; Howard AD; Mills SG; Yang L
    Bioorg Med Chem Lett; 2011 Jun; 21(11):3390-4. PubMed ID: 21514824
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Discovery of novel selective GPR120 agonists with potent anti-diabetic activity by hybrid design.
    Sheng R; Yang L; Zhang Y; Xing E; Shi R; Wen X; Wang H; Sun H
    Bioorg Med Chem Lett; 2018 Aug; 28(15):2599-2604. PubMed ID: 29980358
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Discovery of Pyrrolidine-Containing GPR40 Agonists: Stereochemistry Effects a Change in Binding Mode.
    Jurica EA; Wu X; Williams KN; Hernandez AS; Nirschl DS; Rampulla RA; Mathur A; Zhou M; Cao G; Xie C; Jacob B; Cai H; Wang T; Murphy BJ; Liu H; Xu C; Kunselman LK; Hicks MB; Sun Q; Schnur DM; Sitkoff DF; Dierks EA; Apedo A; Moore DB; Foster KA; Cvijic ME; Panemangalore R; Flynn NA; Maxwell BD; Hong Y; Tian Y; Wilkes JJ; Zinker BA; Whaley JM; Barrish JC; Robl JA; Ewing WR; Ellsworth BA
    J Med Chem; 2017 Feb; 60(4):1417-1431. PubMed ID: 28112924
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Design, synthesis, and biological evaluation of deuterated phenylpropionic acid derivatives as potent and long-acting free fatty acid receptor 1 agonists.
    Li Z; Liu C; Xu X; Shi W; Li H; Dai Y; Cai X; Huang W; Qian H
    Bioorg Chem; 2018 Feb; 76():303-313. PubMed ID: 29223807
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Design and Identification of a GPR40 Full Agonist (
    Furukawa H; Miyamoto Y; Hirata Y; Watanabe K; Hitomi Y; Yoshitomi Y; Aida J; Noguchi N; Takakura N; Takami K; Miwatashi S; Hirozane Y; Hamada T; Ito R; Ookawara M; Moritoh Y; Watanabe M; Maekawa T
    J Med Chem; 2020 Sep; 63(18):10352-10379. PubMed ID: 32900194
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Identification of a potent and selective free fatty acid receptor 1 (FFA1/GPR40) agonist with favorable physicochemical and in vitro ADME properties.
    Christiansen E; Urban C; Grundmann M; Due-Hansen ME; Hagesaether E; Schmidt J; Pardo L; Ullrich S; Kostenis E; Kassack M; Ulven T
    J Med Chem; 2011 Oct; 54(19):6691-703. PubMed ID: 21854074
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Potentiation of insulin secretion and improvement of glucose intolerance by combining a novel G protein-coupled receptor 40 agonist DS-1558 with glucagon-like peptide-1 receptor agonists.
    Nakashima R; Yano T; Ogawa J; Tanaka N; Toda N; Yoshida M; Takano R; Inoue M; Honda T; Kume S; Matsumoto K
    Eur J Pharmacol; 2014 Aug; 737():194-201. PubMed ID: 24858371
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Chronic treatment with novel GPR40 agonists improve whole-body glucose metabolism based on the glucose-dependent insulin secretion.
    Tanaka H; Yoshida S; Oshima H; Minoura H; Negoro K; Yamazaki T; Sakuda S; Iwasaki F; Matsui T; Shibasaki M
    J Pharmacol Exp Ther; 2013 Sep; 346(3):443-52. PubMed ID: 23853170
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Design, synthesis, and biological evaluation of novel dual FFA1 and PPARδ agonists possessing phenoxyacetic acid scaffold.
    Zhou Z; Cai Z; Zhang C; Yang B; Chen L; He Y; Zhang L; Li Z
    Bioorg Med Chem; 2022 Feb; 56():116615. PubMed ID: 35051813
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Acute administration of GPR40 receptor agonist potentiates glucose-stimulated insulin secretion in vivo in the rat.
    Doshi LS; Brahma MK; Sayyed SG; Dixit AV; Chandak PG; Pamidiboina V; Motiwala HF; Sharma SD; Nemmani KV
    Metabolism; 2009 Mar; 58(3):333-43. PubMed ID: 19217448
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Evaluation of the hepatotoxicity of the novel GPR40 (FFAR1) agonist CPL207280 in the rat and monkey.
    Bazydlo-Guzenda K; Buda P; Mach M; Pieczykolan J; Kozlowska I; Janiszewski M; Drzazga E; Dominowski J; Ziolkowski H; Wieczorek M; Gad SC
    PLoS One; 2021; 16(9):e0257477. PubMed ID: 34555055
    [TBL] [Abstract][Full Text] [Related]  

  • 52. FFAR1/GPR40: One target, different binding sites, many agonists, no drugs, but a continuous and unprofitable tug-of-war between ligand lipophilicity, activity, and toxicity.
    Governa P; Caroleo MC; Carullo G; Aiello F; Cione E; Manetti F
    Bioorg Med Chem Lett; 2021 Jun; 41():127969. PubMed ID: 33771587
    [TBL] [Abstract][Full Text] [Related]  

  • 53. GPR40 partial agonist MK-2305 lower fasting glucose in the Goto Kakizaki rat via suppression of endogenous glucose production.
    Miller C; Pachanski MJ; Kirkland ME; Kosinski DT; Mane J; Bunzel M; Cao J; Souza S; Thomas-Fowlkes B; Di Salvo J; Weinglass AB; Li X; Myers RW; Knagge K; Carrington PE; Hagmann WK; Trujillo ME
    PLoS One; 2017; 12(5):e0176182. PubMed ID: 28542610
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Discovery of 3-aryl-3-ethoxypropanoic acids as orally active GPR40 agonists.
    Takano R; Yoshida M; Inoue M; Honda T; Nakashima R; Matsumoto K; Yano T; Ogata T; Watanabe N; Toda N
    Bioorg Med Chem Lett; 2014 Jul; 24(13):2949-53. PubMed ID: 24835985
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Discovery of phenylsulfonyl acetic acid derivatives with improved efficacy and safety as potent free fatty acid receptor 1 agonists for the treatment of type 2 diabetes.
    Li Z; Liu C; Xu X; Qiu Q; Su X; Dai Y; Yang J; Li H; Shi W; Liao C; Pan M; Huang W; Qian H
    Eur J Med Chem; 2017 Sep; 138():458-479. PubMed ID: 28689096
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Design and synthesis of novel and potent GPR119 agonists with a spirocyclic structure.
    Harada K; Mizukami J; Kadowaki S; Matsuda I; Watanabe T; Oe Y; Kodama Y; Aoki K; Suwa K; Fukuda S; Yata S; Inaba T
    Bioorg Med Chem Lett; 2018 Apr; 28(7):1228-1233. PubMed ID: 29519733
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Structure-based optimization of free fatty acid receptor 1 agonists bearing thiazole scaffold.
    Li Z; Xu X; Hou J; Wang S; Jiang H; Zhang L
    Bioorg Chem; 2018 Apr; 77():429-435. PubMed ID: 29433092
    [TBL] [Abstract][Full Text] [Related]  

  • 58. GPR40 Agonists for the Treatment of Type 2 Diabetes Mellitus: Benefits and Challenges.
    Mohammad S
    Curr Drug Targets; 2016; 17(11):1292-300. PubMed ID: 26648068
    [TBL] [Abstract][Full Text] [Related]  

  • 59. TAK-875, an orally available G protein-coupled receptor 40/free fatty acid receptor 1 agonist, enhances glucose-dependent insulin secretion and improves both postprandial and fasting hyperglycemia in type 2 diabetic rats.
    Tsujihata Y; Ito R; Suzuki M; Harada A; Negoro N; Yasuma T; Momose Y; Takeuchi K
    J Pharmacol Exp Ther; 2011 Oct; 339(1):228-37. PubMed ID: 21752941
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Discovery of LY3104607: A Potent and Selective G Protein-Coupled Receptor 40 (GPR40) Agonist with Optimized Pharmacokinetic Properties to Support Once Daily Oral Treatment in Patients with Type 2 Diabetes Mellitus.
    Hamdouchi C; Maiti P; Warshawsky AM; DeBaillie AC; Otto KA; Wilbur KL; Kahl SD; Patel Lewis A; Cardona GR; Zink RW; Chen K; Cr S; Lineswala JP; Neathery GL; Bouaichi C; Diseroad BA; Campbell AN; Sweetana SA; Adams LA; Cabrera O; Ma X; Yumibe NP; Montrose-Rafizadeh C; Chen Y; Miller AR
    J Med Chem; 2018 Feb; 61(3):934-945. PubMed ID: 29236497
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.